Latest Insider Transactions at Karyopharm Therapeutics Inc. (KPTI)
This section provides a real-time view of insider transactions for Karyopharm Therapeutics Inc. (KPTI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Karyopharm Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Karyopharm Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 07
2022
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
1,991
-1.87%
|
$17,919
$9.86 P/Share
|
|
Feb 07
2022
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,704
-1.29%
|
$15,336
$9.86 P/Share
|
|
Dec 02
2021
|
Stephen Mitchener SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
499
-13.15%
|
$2,994
$6.69 P/Share
|
|
Jul 12
2021
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
665
-0.5%
|
$5,985
$9.73 P/Share
|
|
Jun 30
2021
|
Sohanya Roshan Cheng EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
-
|
|
Jun 02
2021
|
Stephen Mitchener SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
528
-17.6%
|
$4,752
$9.29 P/Share
|
|
Jun 01
2021
|
Michael Mason EVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+8.76%
|
-
|
|
May 30
2021
|
Stephen Mitchener SVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+33.33%
|
-
|
|
May 07
2021
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
23,250
+15.0%
|
$186,000
$8.6 P/Share
|
|
May 06
2021
|
Garen G Bohlin |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$28,000
$7.82 P/Share
|
|
May 03
2021
|
Richard A. Paulson President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
373,200
+50.0%
|
-
|
|
Mar 18
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
4,000
-0.56%
|
$48,000
$12.39 P/Share
|
|
Mar 18
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
4,000
-0.56%
|
$48,000
$12.39 P/Share
|
|
Feb 25
2021
|
Michael Kauffman Director |
BUY
Grant, award, or other acquisition
|
Indirect |
57,200
+5.85%
|
-
|
|
Feb 25
2021
|
Michael Kauffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
57,200
+7.37%
|
-
|
|
Feb 25
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
57,200
+7.37%
|
-
|
|
Feb 25
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,200
+5.85%
|
-
|
|
Feb 25
2021
|
John Demaree Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,849
+39.78%
|
-
|
|
Feb 25
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,013
+17.41%
|
-
|
|
Feb 25
2021
|
Tanya Lewis EVP, Chief Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
22,013
+32.65%
|
-
|
|
Feb 25
2021
|
Michael Mason EVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
22,013
+29.84%
|
-
|
|
Feb 25
2021
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,013
+16.97%
|
-
|
|
Feb 18
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
9,495
-1.21%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
9,495
-1.62%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
9,495
-1.62%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,495
-1.21%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
2,887
-5.89%
|
$40,418
$14.83 P/Share
|
|
Feb 18
2021
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,186
-2.24%
|
$16,604
$14.83 P/Share
|
|
Feb 15
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
21,800
+2.7%
|
-
|
|
Feb 15
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,800
+3.59%
|
-
|
|
Feb 15
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
21,800
+3.59%
|
-
|
|
Feb 15
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,800
+2.7%
|
-
|
|
Feb 15
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,675
+16.49%
|
-
|
|
Feb 15
2021
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,850
+8.39%
|
-
|
|
Feb 11
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
6,642
-0.86%
|
$99,630
$15.52 P/Share
|
|
Feb 11
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
6,601
-1.16%
|
$99,015
$15.52 P/Share
|
|
Feb 11
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
6,601
-1.16%
|
$99,015
$15.52 P/Share
|
|
Feb 11
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,642
-0.86%
|
$99,630
$15.52 P/Share
|
|
Feb 11
2021
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
2,858
-35.07%
|
$42,870
$15.52 P/Share
|
|
Feb 11
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
2,046
-4.94%
|
$30,690
$15.52 P/Share
|
|
Feb 11
2021
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,748
-3.5%
|
$26,220
$15.52 P/Share
|
|
Feb 11
2021
|
Tanya Lewis EVP, Chief Reg. Affairs |
SELL
Open market or private sale
|
Direct |
2,046
-33.06%
|
$30,690
$15.52 P/Share
|
|
Feb 05
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,300
+1.82%
|
-
|
|
Feb 05
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,300
+2.45%
|
-
|
|
Feb 05
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,300
+2.45%
|
-
|
|
Feb 05
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,300
+1.82%
|
-
|
|
Feb 05
2021
|
Michael Mason EVP, CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,150
+50.0%
|
-
|
|
Feb 05
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,650
+12.01%
|
-
|
|
Feb 05
2021
|
Tanya Lewis EVP, Chief Reg. Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
5,650
+47.72%
|
-
|
|
Feb 05
2021
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,650
+10.18%
|
-
|